On May 28, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported that its CEO participated in a Virtual Investor "What This Means" interview focused on the Company’s recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the interview, Mr. Gaslightwala highlighted the significance of Akari’s first ASCO (Free ASCO Whitepaper) abstract acceptance and discussed newly presented preclinical data demonstrating combination synergy between Akari’s differentiated spliceosome-modulating ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models. The data further supports the potential of Akari’s proprietary PH1 payload platform to address the most difficult-to-treat cancers with significant unmet met, such as KRAS-driven tumors.
"The acceptance of our data at ASCO (Free ASCO Whitepaper) represents an important validation milestone for Akari and reinforces the growing excitement surrounding our differentiated ADC platform," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "We believe AKTX-101 and our novel spliceosome-modulating payload approach have the potential to redefine how difficult-to-treat KRAS-driven cancers are targeted, particularly in patient populations where current therapeutic options remain limited."
The discussion also explored the key findings from the accepted abstract and what management believes differentiates Akari’s approach within the rapidly evolving ADC landscape, including the Company’s novel RNA splicing modulation mechanism designed to enhance anti-tumor activity and broaden therapeutic applicability across multiple solid tumor indications.
In addition, Mr. Gaslightwala outlined several anticipated milestones investors should monitor, including continued advancement of Akari’s PH1 spliceosome-modulating payload platform and the Company’s targeted initiation of a Phase 1 first-in-human clinical trial by mid-2027.
The Virtual Investor "What This Means" segment featuring Akari Therapeutics is now available here.
(Press release, Akari Therapeutics, MAY 28, 2026, View Source [SID1234666139])